Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer

Bolla, 2002, Long-term results with immediate androgen suppression and external irradiation in patients with locally advance prostate cancer (an EORTC study): A phase III randomized trial, Lancet, 360, 103, 10.1016/S0140-6736(02)09408-4 D'Amico, 2004, 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer, JAMA, 292, 821, 10.1001/jama.292.7.821 Horwitz, 2008, Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, J Clin Oncol, 26, 2497, 10.1200/JCO.2007.14.9021 Zelefsky, 2002, High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients, Int J Radiat Oncol Biol Phys, 53, 1111, 10.1016/S0360-3016(02)02857-2 Viani, 2009, Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials, Int J Radiat Oncol Biol Phys, 74, 1405, 10.1016/j.ijrobp.2008.10.091 Michalski, 2015, A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer [Abstract], J Clin Oncol, 33 Shahinian, 2005, Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 352, 154, 10.1056/NEJMoa041943 Keating, 2006, Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J Clin Oncol, 24, 4448, 10.1200/JCO.2006.06.2497 Edelman, 2012, High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes, Int J Radiat Oncol Biol Phys, 83, 1473, 10.1016/j.ijrobp.2011.10.036 Castle, 2013, Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?, Int J Radiat Oncol Biol Phys, 85, 693, 10.1016/j.ijrobp.2012.06.030 Valicente, 2011, Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06, Int J Radiat Oncol Biol Phys, 79, 1323, 10.1016/j.ijrobp.2010.01.009 Krauss, 2011, Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 80, 1064, 10.1016/j.ijrobp.2010.04.004 Dubray, 2011, Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial [Abstract], J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.4521 Nadib, 2015, A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy [Abstract], J Clin Oncol, 33 Mohler, 2010, NCCN clinical practice guidelines in oncology: prostate cancer, J Natl Compr Canc Netw, 8, 162, 10.6004/jnccn.2010.0012 Gadia, 2013, Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer, Radiat Oncol, 8, 285, 10.1186/1748-717X-8-285 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 Victora, 1997, The role of conceptual frameworks in epidemiological analysis: a hierarchical approach, Int J Epidemiol, 26, 224, 10.1093/ije/26.1.224 Zumsteg, 2013, A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy, Eur Urol, 64, 895, 10.1016/j.eururo.2013.03.033 Khuntia, 2004, Recurrence-free survival rates after external beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?, Cancer, 100, 1283, 10.1002/cncr.20093 Zapatero, 2015, High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomized, controlled, phase III trial, Lancet Oncol, 16, 320, 10.1016/S1470-2045(15)70045-8 Zagars, 1995, Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome, Urology, 45, 476, 10.1016/S0090-4295(99)80019-3 Liebig, 2009, Perineural invasion in cancer: A review of the literature, Cancer, 115, 3379, 10.1002/cncr.24396 Bonin, 1997, Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy, Cancer, 79, 75, 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3